Educational Panel : Reshaping Tumor Microenvironments via Immunotherapies

feb 11, 2019: 9 a.m. - 10 a.m.
Shubert Complex

Current CAR-T therapies have shown significant benefits attacking hematological malignancies, and currently approved checkpoint inhibitors are highly but selectively effective in their impact on solid tumors. This session will examine the next wave of innovation in immunotherapies for leveraging knowledge of how tumor microenvironments develop to create treatments able to demonstrate more durable effects on shrinking tumors across wider ranges of patients.


Moderator: Jotin Marango, MD, PhD, Managing Directior, Sr. Research Analyst, Roth Capital Partners, LLC


Lewis Bender
Founder and CEO

Sabine Chlosta
Chief Medical Officer

Eric Falcand
Vice President, Head o...

Jotin Marango
Managing Director, Sen...